Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 6:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 213 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Duloxetine hydrochloride Clear all
Completed Phase 3 Interventional Accepts healthy volunteers

Study Evaluating the Effects of DVS SR and Duloxetine on the Pharmacokinetics of Desipramine in Healthy Subjects

NCT00366652
View directory record Official record
Conditions
Depression, Depressive Disorder, Depressive Disorder, Major
Interventions
desvenlafaxine SR, desipramine, duloxetine
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated May 28, 2007 · Synced Oct 11, 2026, 6:13 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Test the Use of Duloxetine for Pain in MS

NCT00457730
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Duloxetine, Placebo
Drug
Lead sponsor
Brown, Theodore R., M.D., MPH
Individual
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Apr 27, 2015 · Synced Oct 11, 2026, 6:13 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder

NCT00854100
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Antidepressant + placebo, Antidepressant + cariprazine (0.1-0.3 mg/day), Antidepressant + cariprazine (1-2 mg/d)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
41
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Arcadia, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 11, 2026, 6:13 AM EDT
Completed Phase 4 Interventional Results available

Study of Brain Response to Emotional Pictures Using a fMRI While on Duloxetine

NCT00532480
View directory record Official record
Conditions
Major Depression
Interventions
Duloxetine
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 3, 2016 · Synced Oct 11, 2026, 6:13 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Duloxetine RCT on Postop TKA Outcomes

NCT05086393
View directory record Official record
Conditions
Pain, Postoperative, Total Knee Arthroplasty
Interventions
Duloxetine, Placebos
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
241 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 11, 2026, 6:13 AM EDT
Completed Not applicable Interventional

Assessment of Cognitive Functioning Before and After Treatment With Duloxetine

NCT00933439
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Duloxetine
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2013 · Synced Oct 11, 2026, 6:13 AM EDT
Completed Phase 1 Interventional

Multiple Ascending Dose Phase 1 Study of ALA-3000

NCT06965569
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
ALA-3000, Placebo, escitalopram, sertraline, duloxetine or venlafaxine XR
Drug
Lead sponsor
Alar Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
4
States / cities
Little Rock, Arkansas • St Louis, Missouri • Eatontown, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 11, 2026, 6:13 AM EDT
Terminated Phase 4 Interventional Results available

Duloxetine for the Treatment of Chronic Pelvic Pain

NCT01451606
View directory record Official record
Conditions
Pelvis Pain Chronic
Interventions
Duloxetine, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Oct 11, 2026, 6:13 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder

NCT01564862
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
vortioxetine (Lu AA21004), Duloxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
62
States / cities
Tucson, Arizona • Little Rock, Arkansas • Bellflower, California + 59 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2015 · Synced Oct 11, 2026, 6:13 AM EDT
Completed Phase 3 Interventional Results available

A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression

NCT02497287
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Esketamine (Intranasal Spray), Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
16
States / cities
New Haven, Connecticut • Miami, Florida • Marietta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 11, 2026, 6:13 AM EDT
Terminated Phase 4 Interventional Results available

Switching to Duloxetine to Ameliorate SSRI-Induced Sexual Dysfunction

NCT00398632
View directory record Official record
Conditions
Depression
Interventions
Duloxetine
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 11, 2026, 6:13 AM EDT
Completed Phase 3 Interventional Results available

A Study in the Treatment of Children and Adolescents With Major Depressive Disorder

NCT00849901
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
duloxetine, Placebo, fluoxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
7 Years to 17 Years
Enrollment
337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
24
States / cities
Costa Mesa, California • Irvine, California • Palo Alto, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 11, 2026, 6:13 AM EDT
Completed Not applicable Interventional Results available

Evaluation of Stepped Care for Chronic Pain in Iraq/Afghanistan Veterans (ESCAPE)

NCT00386243
View directory record Official record
Conditions
Low Back Pain, Pain, Pain, Intractable
Interventions
Cognitive behavioral therapy, Pain self-management program, Co-Analgesic Therapy, Opioid Analgesics
Behavioral · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 11, 2026, 6:13 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT02417064
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
37
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Garden Grove, California + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 11, 2026, 6:13 AM EDT
Withdrawn Phase 4 Interventional

Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities

NCT06107829
View directory record Official record
Conditions
Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities
Interventions
Valbenazine Oral Capsule
Drug
Lead sponsor
Stephen Ruedrich
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Oct 11, 2026, 6:13 AM EDT
Recruiting No phase listed Observational

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

NCT03511118
View directory record Official record
Conditions
Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI
Interventions
Tranexamic acid (TXA), labetalol, metformin, nifedipine, clindamycin, oxycodone, azithromycin, escitalopram, sertraline, ondansetron, Ciprofloxacin, Doxycycline, Levofloxacin, Methylphenidate, Sumatriptan, Citalopram, Cyclobenzaprine, Furosemide, Gabapentin, Hydrochlorothiazide, Hydroxyurea, Rosuvastatin, Topiramate, Trazodone, Valganciclovir, Venlafaxine, Verapamil, Remdesivir, Anakinra, Tocilizumab, Fluvoxamine, Amoxicillin, Bupropion, Duloxetine, Hydrocodone, Levetiracetam, Paroxetine, Buprenorphine
Drug
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
20
States / cities
La Jolla, California • Loma Linda, California • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 11, 2026, 6:13 AM EDT
Completed Phase 4 Interventional Results available

Duloxetine Treatment in Elderly With Dysthymia

NCT01852383
View directory record Official record
Conditions
Depression, Dysthymic Disorder
Interventions
Duloxetine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
60 Years to 95 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2014 · Synced Oct 11, 2026, 6:13 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.

NCT01288079
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
TC-5214, Duloxetine, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
25
States / cities
Beverly Hills, California • Chino, California • Garden Grove, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2012 · Synced Oct 11, 2026, 6:13 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Duloxetine Versus Placebo in Patients Taking a Nonsteroidal Anti-inflammatory Drug (NSAID) for Knee Pain Due to Osteoarthritis

NCT01018680
View directory record Official record
Conditions
Osteoarthritis Knee Pain
Interventions
Duloxetine, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
40 Years and older
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
32
States / cities
Tucson, Arizona • Garden Grove, California • Long Beach, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2012 · Synced Oct 11, 2026, 6:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Microbiome Derived Metabolism and Pharmacokinetics

NCT05065671
View directory record Official record
Conditions
Microbial Colonization
Interventions
Tolcapone 100 MG, Duloxetine 20 MG
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Somerville, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 11, 2026, 6:13 AM EDT
Recruiting Phase 2 Interventional

Scrambler Therapy With Duloxetine-based Usual Care vs Duloxetine-based Usual Care for Chemotherapy-induced Peripheral Neuropathy.

NCT06914557
View directory record Official record
Conditions
CIPN - Chemotherapy-Induced Peripheral Neuropathy, Pain
Interventions
Scrambler Therapy, Questionnaire and Physical Exam
Device · Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 11, 2026, 6:13 AM EDT
Completed Phase 4 Interventional Results available

A Study in Depression and Associated Painful Physical Symptoms

NCT01070329
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Duloxetine, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
32
States / cities
Sherman Oaks, California • Cromwell, Connecticut • Fort Lauderdale, Florida + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2012 · Synced Oct 11, 2026, 6:13 AM EDT
Completed Phase 2 Interventional Results available

Treating Negative Affect in Low Back Pain Patients

NCT04747314
View directory record Official record
Conditions
Chronic Low Back Pain, Negative Affectivity
Interventions
Antidepressant, Enhanced Fear Avoidance Rehabilitation
Drug · Other
Lead sponsor
Ajay Wasan, MD, Msc
Other
Eligibility
18 Years to 75 Years
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Chestnut Hill, Massachusetts • Rochester, Minnesota • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 11, 2026, 6:13 AM EDT
Completed Phase 4 Interventional Results available

Antidepressant Response in the Treatment of Depressive Symptoms and Frailty Characteristics in Older Adults

NCT01973283
View directory record Official record
Conditions
Major Depressive Disorder, Dysthymic Disorder, Depressive Disorder, NOS
Interventions
Antidepressant Medication
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
60 Years to 95 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 29, 2021 · Synced Oct 11, 2026, 6:13 AM EDT